Immunotherapy drug durvalumab tested to stop bladder cancer return

NCT ID NCT03768570

Ongoing Disease control Sponsor: Canadian Cancer Trials Group Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial tests whether adding the immunotherapy drug durvalumab after surgery, chemotherapy, and radiation can help prevent bladder cancer from coming back in people with muscle-invasive bladder cancer. About 82 participants will receive either durvalumab or a placebo for up to 12 months. The study measures how long people stay cancer-free and looks at recurrence patterns.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Durvalumab (an immunotherapy drug)
What this could lead to: If it works, this could point toward a new treatment option that helps prevent bladder cancer from coming back after standard therapy.
What could go wrong: This is a small, early-phase trial with only 82 participants, so results may not apply to everyone. Durvalumab can cause immune-related side effects like inflammation in the lungs, liver, or skin.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infiltrating bladder urothelial carcinoma urinary bladder carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLADDER CANCER

Contacts and locations

Show contact details

Locations

Allan Blair Cancer Centre

Regina, Saskatchewan, S4T 7T1, Canada
BCCA - Vancouver Cancer Centre

Vancouver, British Columbia, V5Z 4E6, Canada
Charing Cross Hospital

London, England, VV6 8RF, United Kingdom
Cross Cancer Institute

Edmonton, Alberta, T6G 1Z2, Canada
Health Sciences North

Greater Sudbury, Ontario, P3E 5J1, Canada
Hospital 12 de Octubre

Madrid, 28041, Spain
Hospital Clinic i Provincial

Barcelona, 08036, Spain
Hospital Clinico San Carlos

Madrid, 28040, Spain
Hospital Madrid Norte Sanchinarro

Madrid, 28050, Spain
Hospital Universitario La Paz

Madrid, 28046, Spain
Hospital Universitario Marques de Valdecilla

Santander, 39008, Spain
Hospital de la Santa Creu i Sant Pau

Barcelona, 08041, Spain
Instituto Valenciano de Oncologia

Valencia, 46009, Spain
Juravinski Cancer Centre at Hamilton Health Sciences

Hamilton, Ontario, L8V 5C2, Canada
Kingston Health Sciences Centre

Kingston, Ontario, K7L 2V7, Canada
London Regional Cancer Program

London, Ontario, N6A 5W9, Canada
Nottingham University Hospitals City Hospital Campus

Nottingham, NG5 1PB, United Kingdom
Ottawa Hospital Research Institute

Ottawa, Ontario, K1H 8L6, Canada
Royal Cornwall Hospitals NHS Trust

Cornwall, England, TR1 3LQ, United Kingdom
Royal Devon and Exeter Hospital

Exeter, Devon, EX2 5DW, United Kingdom
Royal Preston Hospital

Lancashire, England, PR2 9HT, United Kingdom
Saskatoon Cancer Centre

Saskatoon, Saskatchewan, S7N 4H4, Canada
Stronach Regional Health Centre at Southlake

Newmarket, Ontario, L3Y 2P9, Canada
The Christie NHS Foundation Trust

Manchester, England, United Kingdom
The Jewish General Hospital

Montreal, Quebec, H3T 1E2, Canada
The Research Institute of the McGill University

Montreal, Quebec, H4A 3J1, Canada
The Royal Marsden NHS Foundation Trust - Sutton

Surrey, England, United Kingdom
Thunder Bay Regional Health Sciences Centre/

Thunder Bay, Ontario, P7B 6V4, Canada
Tom Baker Cancer Centre

Calgary, Alberta, T2N 4N2, Canada
University Health Network

Toronto, Ontario, M5G 2M9, Canada
University Hospital Southampton NHS Foundation Trust

Southampton, Hampshire, SO16 6YD, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.